United States

ReCode Therapeutics is a genetic medicines company that uses a next-generation, selective organ targeting (SORT) lipid nanoparticle (LNP) platform to deliver mRNA and gene correction therapeutics to target organs and cells beyond the liver. Their lead programs focus on primary ciliary dyskinesia and cystic fibrosis, and they are expanding their pipeline with therapeutics that use mRNA-mediated replacement and gene correction in target organs with precision targeting of disease-relevant cells.

Google

产品经理

数据科学家

ReCode Therapeutics

ReCode Therapeutics 开放职位

准备好提升您的职业生涯了吗？查看ReCode Therapeutics的这些开放职位。